Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,211
  • Shares Outstanding, K 41,272
  • Annual Sales, $ 10,090 K
  • Annual Income, $ -132,740 K
  • 60-Month Beta 0.77
  • Price/Sales 9.12
  • Price/Cash Flow N/A
  • Price/Book 0.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.75
  • Low Estimate -0.80
  • Prior Year -1.01
  • Growth Rate Est. (year over year) +23.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.93 +14.51%
on 06/28/19
5.37 -58.85%
on 06/20/19
-2.46 (-52.68%)
since 06/14/19
3-Month
1.93 +14.51%
on 06/28/19
7.15 -69.10%
on 04/29/19
-3.29 (-59.82%)
since 04/16/19
52-Week
1.93 +14.51%
on 06/28/19
20.80 -89.38%
on 07/17/18
-18.29 (-89.22%)
since 07/16/18

Most Recent Stories

More News
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ:...

ACRS : 2.21 (-0.90%)
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ:...

ACRS : 2.21 (-0.90%)
What Makes Aclaris (ACRS) a New Buy Stock

Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRS : 2.21 (-0.90%)
Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE(R) (Oxymetazoline Hydrochloride) Cream, 1%

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark...

ACRS : 2.21 (-0.90%)
Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Pintec, Sealed Air, and Aclaris Therapeutics on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Pintec Technology Holdings, Ltd., Sealed Air Corporation, and Aclaris Therapeutics, Inc. on behalf of Investors. Our investigation...

SEE : 43.63 (+2.32%)
PT : 3.04 (-15.56%)
ACRS : 2.21 (-0.90%)
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board...

TRVN : 1.05 (-0.94%)
AKBA : 4.05 (-5.15%)
ACRS : 2.21 (-0.90%)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or "the Company") (NASDAQ:...

ACRS : 2.21 (-0.90%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

ACRS : 2.21 (-0.90%)
Bragar Eagel & Squire, P.C. Reminds Investors of Its Investigations of Aclaris Therapeutics, electroCore, Pintec, and Sealed Air on Behalf of Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Aclaris Therapeutics, Inc., electroCore, Inc., Pintec Technology Holdings, Ltd., and Sealed Air Corporation on behalf of Investors....

ECOR : 1.40 (-13.04%)
SEE : 43.63 (+2.32%)
PT : 3.04 (-15.56%)
ACRS : 2.21 (-0.90%)
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

Glancy Prongay & Murray LLP ("GPM") announces the continuation of its investigation on behalf of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") (NASDAQ: ACRS) investors concerning the Company...

ACRS : 2.21 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ACRS with:

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

2nd Resistance Point 2.29
1st Resistance Point 2.25
Last Price 2.21
1st Support Level 2.17
2nd Support Level 2.13

See More

52-Week High 20.80
Fibonacci 61.8% 13.59
Fibonacci 50% 11.36
Fibonacci 38.2% 9.14
Last Price 2.21
52-Week Low 1.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar